The alarmin S100A8/A9 is implicated in sterile inflammation-induced bone resorption and has been shown to increase the bone-resorptive capacity of mature osteoclasts. Here, we investigated the effects of S100A9 on osteoclast differentiation from human CD14 + circulating precursors. Hereto, human CD14 + monocytes were isolated and differentiated toward osteoclasts with M-CSF and receptor activator of NF-kB (RANK) ligand (RANKL) in the presence or absence of S100A9. Tartrate-resistant acid phosphatase staining showed that exposure to S100A9 during monocyte-to-osteoclast differentiation strongly decreased the numbers of multinucleated osteoclasts. This was underlined by a decreased resorption of a hydroxyapatite-like coating. The thus differentiated cells showed a high mRNA and protein production of proinflammatory factors after 16 h of exposure. In contrast, at d 4, the cells showed a decreased production of the osteoclast-promoting protein TNF-a. Interestingly, S100A9 exposure during the first 16 h of culture only was sufficient to reduce osteoclastogenesis. Using fluorescently labeled RANKL, we showed that, within this time frame, S100A9 inhibited the M-CSF-mediated induction of RANK. Chromatin immunoprecipitation showed that this was associated with changes in various histone marks at the epigenetic level. This S100A9-induced reduction in RANK was in part recovered by blocking TNF-a but not IL-1. Together, our data show that S100A9 impedes monocyte-to-osteoclast differentiation, probably via a reduction in RANK expression.-Di Ceglie, I., Blom, A. B., Davar, R., Logie, C., Martens, J. H. A., Habibi, E., Böttcher, L.-M., Roth, J., Vogl, T., Goodyear, C. S., van der Kraan, P. M., van Lent, P. L., van den Bosch, M. H. The alarmin S100A9 hampers osteoclast differentiation from human circulating precursors by reducing the expression of RANK. FASEB J. 33, 10104-10115 (2019). www.fasebj.org KEY WORDS: S100A8/A9 • epigenetic regulation • bone
Balanced bone turnover is crucial in maintaining skeletal integrity. However, under inflammatory conditions that are present during various rheumatic disorders, bone turnover is disturbed, ultimately resulting in a shift toward resorption.
Osteoclasts are unique in their ability to resorb bone tissue and, together with osteoblasts and osteocytes, are key in the process of bone turnover throughout life (1) (2) (3) .
Both osteoclast differentiation and activation of the resorptive activity are tightly regulated, and therefore, deregulation of these processes, due to hyperinflammation, for example, leads to serious dysfunctioning of the bone tissue (4, 5) .
Osteoclasts differentiate from myeloid precursors by fusion under the influence of M-CSF and receptor activator of NF-kB (RANK) ligand (RANKL), which are normally produced by osteoblasts and stromal cells (6) (7) (8) . The binding of M-CSF to its receptor promotes progenitor survival and proliferation and induces the expression of RANK at the cell surface (9) (10) (11) . Subsequent binding of RANKL to RANK leads to activation of nuclear factor of activated T-cells cytoplasmic 1, culminating in the activation of bone resorption by multinucleated osteoclasts (12, 13) .
A close relation between bone turnover and the immune system has been previously shown by Ginaldi et al. (14) . Various proinflammatory cytokines, such as TNF-a and IL-1b, have been associated with increased bone turnover by affecting osteoclast differentiation and function (4, (15) (16) (17) .
The alarmin S100A8/A9, which belongs to the family of calcium-binding proteins, is historically thought to stimulate innate immune responses. High concentrations of S100A8/A9 are present in the cytosol of neutrophils and monocytes and are released into the extracellular space as a result of cell stress, where they act as damage-associated molecular patterns that activate the immune system mainly via TLR4-dependent signaling cascades (18, 19) . S100A8/A9 (calprotectin) is among the most abundant alarmins under conditions of sterile inflammation that are driven by endogenous danger signals and is used as biomarker for various autoimmune diseases, such as rheumatoid arthritis and Crohn's disease (20) (21) (22) . S100A8/A9 signaling results in the production of proinflammatory mediators in a plethora of cell types, including endothelial cells, monocytes, macrophages, and neutrophils (19, (23) (24) (25) (26) (27) (28) .
In line with this proinflammatory function, S100A8/A9 has been implicated in bone metabolism (29) . We previously showed that addition of S100A8 later during in vitro osteoclastogenesis stimulated the further fusion of mature RANKL-primed osteoclasts and increased their bone-resorbing activity. In agreement with this study, induction of antigen-induced arthritis in S100a9 2/2 mice, which additionally lack S100A8 protein in the periphery, resulted in decreased bone erosion (30) . Together, this indicates a stimulating effect of S100A8/A9 on the bone-resorbing activity of mature osteoclasts. However, the effects of S100A8/A9 on the differentiation of osteoclasts from myeloid precursors and thus the maintenance of the osteoclast population remain unknown. Therefore, in the present study, we set out to determine the effects of S100A9 on monocyte-to-osteoclast differentiation. In addition, we investigated the characteristics of the S100A9-stimulated cells by determining their cytokine profile.
MATERIALS AND METHODS

Differentiation and activation of human osteoclasts
Peripheral blood mononuclear cells were obtained from buffy coats of anonymous healthy donors (obtained from Sanquin blood bank, Nijmegen, The Netherlands) using density gradient centrifugation with Ficoll. Afterwards, CD14+ monocytes were isolated with magnetic-activated cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol. Monocytes were differentiated toward osteoclasts in a-minimum essential medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum and penicillin-streptomycin in the continuous presence of 25 ng/ml human M-CSF from the start of the culture and 50 ng/ml human RANKL from d 1 (both from R&D Systems, Minneapolis, MN, USA). Cells were stimulated with 1 mg/ml recombinant human S100A9 for the entirely length of the culture or for the first 16 h only. IL-1b was inhibited with 10 mg/ml IL-1 receptor antagonist (IL-1RA) from the start of the culture, whereas TNF-a was inhibited using 10 mg/ml etanercept.
S100A9 protein
Recombinant human S100A9 was expressed and purified in the same way as previously described for S100A8 (19) . S100A9 recombinant protein was tested to be endotoxin free, determined with the limulus amebocyte cell lysate assay (Lonza, Basel, Switzerland). Moreover, S100A9 protein lost its activity after heat inactivation to 80°C for 30 min, whereas LPS activity has been shown by Vogl et al. (18) not to be changed at that temperature. The S100A8/A9 heterodimeric complex is the physiologically relevant and bioactive form that is secreted from stressed cells and mainly signals via TLR4. Under high-calcium conditions, such as those present in the extracellular milieu and culture medium, S100A8/A9 heterodimers quickly tetramerize into (S100A8/A9) 2 , thereby losing their TLR4 signaling capacity. Therefore, the S100A9 homodimers, which cannot tetramerize, are widely accepted experimental stimuli that closely mimic S100A8/A9 heterodimer activity (31) . In this study, we used 1 mg/ml of S100A9 to stimulate. In vivo concentrations of S100A8/ A9 are manifold higher in the serum and synovial fluid of rheumatoid arthritis, a disease that is clearly associated with hyperinflammation and increased osteoclast formation (25) .
Tartrate-resistant acid phosphatase staining
Numbers of osteoclasts, defined as multinucleated cells with $3 nuclei, were determined using a tartrate-resistant acid phosphatase (TRAP) staining. Hereto, differentiated osteoclasts were washed with PBS and fixed with 4% paraformaldehyde in PBS for 10 min. Afterwards, TRAP was stained with the leukocyte acid phosphatase kit (MilliporeSigma, Burlington, MA, USA) according to the manufacturer's protocol. The number of TRAP + multinucleated cells ($3 nuclei) was manually quantified with Fiji software (v.1.47; https://fiji.sc/) using 9 photomicrographs/ well taken with a camera attached to a light microscope.
Resorption assay using biomimetic hydroxyapatite-like-coated plates
Osteoclast resorptive capacity was determined using biomimetic hydroxyapatite-like-coated plates that were prepared as previously described by ten Harkel et al. (32) . After differentiation, cells were lysed with H 2 O, and the coated layer was stained with a Von Kossa staining. In short, a 5% aqueous silver nitrate was added and incubated in the dark. Afterwards, wells were washed with water and incubated with 5% sodium carbonate in 4% formalin. The staining was washed out, and the nonstained resorbed areas were quantified using 5 photomicrographs/well using the LAS image-analysis system (Leica Microsystems, Buffalo Grove, IL, USA).
RNA isolation and real-time quantitative PCR
Gene expression was determined using real-time quantitative PCR (qPCR). Total RNA was isolated from cultured cells using Trizol reagent (MilliporeSigma) according to the manufacturer's protocol. Afterwards, RNA was reverse transcribed to cDNA. Real-time qPCR was performed with specific primers and the Sybr Green Master Mix using the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific). Expression levels are presented as 2DC t values normalized to the reference gene glyceraldehyde 3-phosphate dehydrogenase. Fold change was calculated as 2 DDCt , where DDC t was determined by correcting the 2DC t from stimulated samples for the 2DC t of unstimulated control samples.
Strand-specific RNA sequencing
Genome-wide RNA expression was determined with RNA sequencing. Hereto, total RNA was isolated using the RNeasy RNA Extraction Kit (Qiagen, Germantown, Maryland, USA) with on-column DNaseI treatment. rRNA was removed using the Ribo-Zero rRNA Removal Kit (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. The RNA concentration was monitored with a Qubit Fluorometer (Thermo Fisher Scientific), and the RNA quality was evaluated by the Agilent Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, USA) prior to library preparation. First-strand cDNA synthesis was performed using SuperScript III (Thermo Fisher Scientific), followed by synthesis of the second cDNA strand. Then, a strand-specific cDNA library with an approximately 200-bp insert size was constructed using the TruSeq Stranded RNA Sample Preparation kit (Illumina) according to the manufacturer's protocol. For each library, paired-end sequencing (76 nt each end) was then performed on an Illumina HiSeq 2000 machine. These data were used to generate Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway map analyses (33) .
Chromatin immunoprecipitation sequencing
To determine whether changes in expression were associated with changes on the epigenetic level, 4 histone marks were selected for chromatin immunoprecipitation (ChIP)-seq, including H3K4me1, H3K4me3, H3K27ac, and H3K27me3 [Diagenode (Seraing, Belgium) C15410194, C15410003-50, C15410196, and C15410195]. Chromatin harvest and sequencing experiments were carried out based on the standard Blueprint protocol (http:// www.blueprint-epigenome.eu). For ChIP, 1 million cells were collected, after which purified cells were first cross-linked using 1% formaldehyde (MilliporeSigma) and then sonicated to obtain DNA fragments of about 200-300 bp by a Diagenode Bioruptor. Sheared chromatin was incubated with specific antibodies against the 4 histone markers. After immunoprecipitation, the protein-DNA cross-links were reversed, and the isolated DNA was used for qPCR and sequencing analysis. Meanwhile, a portion of chromatin was processed under the same conditions but without the immunoprecipitation step as a control dataset (input DNA). For each sample, an Illumina library was prepared with the Kapa Hyper Prep Kit (Illumina) and then was subjected to 42bp single-end sequencing on the Illumina HiSeq 2000 machine. Sequenced reads were aligned against the University of California-Santa Cruz human reference genome (GRCh37/ hg19) with Burrows-Wheeler Aligner program with default parameters (34) . All alignment files were extended to the estimated fragment length and scaled to RPKM-normalized read coverage files using deepTools (https://deeptools.readthedocs.io/en/develop/#) for visualization (35) .
Protein measurement with Luminex
Protein concentrations in the culture medium were determined with the Luminex multianalyte technology on the Bio-Plex 100 system in combination with magnetic beads (Bio-Rad, Hercules, CA, USA) according to the manufacturer's protocol.
Quantification of RANK
The amount of RANK receptor on the cell membrane was quantified using recombinant RANKL (Peprotech, Rocky Hill, NJ, USA) that was phycoerythrin (PE)-labeled using the Lightning-Link R-Phycoerythrin Conjugation Kit (Expedeon, Heidelberg, Germany). Cells were washed with plain medium and incubated with 500 ng/ml PE-labeled RANKL for 1 h at 37°C. After washing with PBS, cells were stained with the eFluor780 viability dye (Thermo Fisher Scientific) for 30 min. Afterwards, cells were washed and fixed in 1% paraformaldehyde followed by the visualization using the Gallios fluorescence-activated cell sorting machine and analysis using Kaluza 2.0 software (both from Beckman Coulter, Brea, CA, USA). Hereto, first debris was excluded based on forward and side scatter, followed by the selection of single and viable cells. Afterwards, RANK-positive cells were gated based on the autofluorescence of unlabeled cells.
Statistics
Datasets were checked for normality using the D'Agostino and Pearson omnibus or Shapiro-Wilk normality test. Differences between groups with a Gaussian distribution were tested with a paired t test or with a Wilcoxon matched-pairs signed rank test if a Gaussian distribution was not allowed to be assumed. For multiple comparisons, differences were tested using a repeatedmeasures 1-way ANOVA, followed by a Tukey multiple comparison for groups with a Gaussian distribution or with a Friedman test, followed by a Dunn's post test for multiplicity if a Gaussian distribution could not be assumed. All analyses were performed with GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). Values of P , 0.05 were considered significant.
RESULTS
S100A9 hampers monocyte-toosteoclast differentiation
First, to determine whether the alarmin S100A9 altered osteoclastogenesis, monocytes were differentiated toward osteoclasts in the continuous presence or absence of S100A9, and the numbers of TRAP + multinucleated cells (with 3 or more nuclei) were determined at d 6 and 8 after the start of the culture. We observed a significant decrease in TRAP + cells both at d 6 (a mean decrease of 56.8%) and 8 (a mean decrease of 51.6%; Fig. 1A, B ). Next to reduce osteoclast numbers, we observed a decreased cell size of the remaining osteoclasts, whereas the bigger osteoclasts were absent after exposure to S100A9 (Supplemental Fig. S1 ). Furthermore, to determine the functional resorptive capacity of the cells, we cultured cells on dentin slides and on hydroxyapatite-likecoated plates. The cells we obtained with our differentiation protocol showed clear resorption of dentin slides, ensuring that they are osteoclasts and not macrophages or multinucleated foreign body giant cells, which have also been shown to have the capacity to resorb a hydroxyapatite-like coating (Supplemental Fig. S2 ). Moreover, we observed that the eroded area on the hydroxyapatite-like-coated plates was significantly lower after exposure to S100A9 as compared with control samples (a mean relative decrease of 62%; Fig. 1C ). Together, this indicates that S100A9 hampers monocyte-to-osteoclast differentiation.
Exposure to S100A9 results in an acute proinflammatory response Next, because S100A9 has mainly been described as a proinflammatory stimulus for many cell types, we determined the production of proinflammatory factors after 16 h of exposure. Pathway analysis of RNA-seq data showed profound dynamic changes in gene expression in the cytokine-cytokine receptor pathway, confirming the close involvement of S100A9 in immune responses (Supplemental Fig. S3 ). To support these data, RNA expression of selected inflammatory mediators that are associated with osteoclast differentiation was determined. This showed a strongly increased mRNA expression of IL-1B, TNFA, IL-6, and IL-8 (a mean 4.8-, 1.6-, 677-, and 6.7-fold increase, respectively), whereas IL-10 was significantly down-regulated (a mean 1.7-fold decrease; Fig. 2A ). Validation of these findings at the protein level showed a significant increase in IL-1b, TNF-a, IL-6, and IL-8 (a mean 17.6-, 15.9-, 493-, and 4.8-fold increase, respectively), in line with the mRNA expression. However, although we observed a decrease in IL-10 mRNA, IL-10 protein levels were unexpectedly significantly increased (a mean 12.6fold increase; Fig. 2B ).
Long-term exposure to S100A9 results in a decreased proinflammatory status Because nowadays more immunomodulatory effects of S100 alarmins are recognized next to their proinflammatory function, we determined whether a relatively long-term exposure for 4 d led to a reduced proinflammatory Figure 1 . S100A9 hampers monocyte-to-osteoclast differentiation. CD14+ monocytes were isolated from buffy coats and differentiated toward osteoclasts with continuous presence of 25 ng/ml M-CSF and 50 ng/ml RANKL from d 1 in the presence or absence of 1 mg/ml S100A9 from the start of the culture. A, B) Exposure to S100A9 decreased the numbers of osteoclasts, as determined with a TRAP staining, both at d 6 (A) and 8 (B) after start of the culture as compared with control samples without S100A9 (n = 8 independent donors). Indeed, quantification of the number of multinucleated osteoclasts (cells with $3 nuclei) showed a significantly lower osteoclast number at both days. C ) Underlining this reduced number of osteoclasts, resorption at d 10 (n = 10 independent donors) was significantly decreased upon exposure to S100A9, as determined with hydroxyapatitelike-coated plates. phenotype of the cells. IL-1b and IL-6 were still increased in most donors, although to a much lesser extent than after 16 h of cultures, but only IL-6 reached significance. Interestingly, the vast majority of donors showed a mildto-moderate decrease in the secretion of TNF-a (a mean 11.7-fold decrease), a factor that is known to further fine tune the differentiation of osteoclasts ( Fig. 3) .
S100A9 mainly affects osteoclastogenesis during the first 16 h of culture
Because only a 16 h exposure of monocytes to S100A9 showed profound dynamic regulation of many members of the cytokine-cytokine receptor pathway that are known to affect osteoclast differentiation, we set out to investigate whether already such a short-term exposure of monocytes to S100A9 was sufficient to decrease the number of osteoclasts at d 6 and 8 and their resorptive capacity at d 10, as was shown in the continuous presence of S100A9. Interestingly, this resulted in a decreased number of TRAP + multinucleated cells at both d 6 (a mean decrease of 42.1%) and 8 (a mean decrease of 9.2%) in the vast majority of donors, although d 8 did not reach significance (Fig. 4A, B) . Moreover, quantification of the resorbed area in hydroxyapatite-like-coated plates showed a significant reduction in osteoclast resorptive activity after S100A9 exposure at d 10 (a mean relative decrease of 34%; Fig. 4C ).
Reduced RANK expression after exposure to S100A9
In the next set of experiments, we set out to determine a possible mechanism underlying the S100A9-mediated decrease in osteoclast differentiation. Hereto, cells that were cultured either in the presence or absence of S100A9 were harvested after 1 d and subjected to RNA-seq analysis. Pathway analysis for osteoclast differentiation showed that C-FMS, the gene encoding the M-CSF receptor and its intracellular signaling, was not decreased upon exposure of monocytes to S100A9, suggesting that this might not cause the decreased osteoclast differentiation. In contrast, the RANK-encoding TNFRSF11A and its downstream signaling seemed to be reduced after S100A9 exposure (Fig. 5A) . Next, we validated these findings in multiple donors using real-time qPCR. As expected, culturing with M-CSF strongly increased the expression of TNFRSF11A (a mean 3240-fold increase), but exposure to S100A9 potently blocked this M-CSF-mediated increase in TNFRSF11A expression (a mean 24.7-fold decrease compared with samples without S100A9; Fig. 5B ). Figure 2 . Short-term exposure to S100A9 results in an acute proinflammatory response. CD14+ monocytes, obtained from buffy coats, were treated with 25 ng/ml M-CSF in the presence or absence of 1 mg/ml S100A9 for 16 h. A) Real-time qPCR (n = 8 independent donors) showed that exposure to S100A9 significantly increased the mRNA expression of the proinflammatory mediators IL-1B, TNFA, IL-6, and IL-8 and significantly decreased the expression of the anti-inflammatory cytokine IL-10 compared with control samples without S100A9. Validation of these results on the protein levels (n = 11 independent donors) using Luminex analysis of the culture supernatant showed that exposure to S100A9 increased secretion of IL-1b, TNF-a, IL-6, and IL-8 compared with control samples that were not exposed to S100A9. B) In contrast to the mRNA expression, protein secretion of IL-10 was also significantly increased upon exposure to S100A9. Before-after graphs are shown, with samples from the same donor connected with lines. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. *P , 0.05, **P , 0.01, ***P , 0.001 vs. control samples without S100A9 as measured by Wilcoxon matched-pairs signed rank test.
Likewise, we observed a strongly increased expression of C-FMS after culturing with M-CSF compared with freshly isolated cells (a mean 20.1-fold increase), but in agreement with the RNA-seq data, we observed no significant decrease in C-FMS (a mean 1.1-fold increase; Fig. 5C ). To examine whether altered expression of TNFRSF11A upon S100A9 treatment during osteoclast differentiation is epigenetically regulated, we performed ChIP-seq using antibodies for 3 histone marks associated with gene activity (H3K4me3, H3K4me1, and H3K27ac) and 1 associated with gene repression (H3K27me3). This revealed that the promoter marks H3K4me3 and H3K27ac were decreased at the TNFRSF11A gene after S100A9 treatment (Fig. 5D ). These results suggest that S100A9-induced chromatin alterations decreased the TNFRSF11A gene activity. In contrast, although H3K27ac at the C-FMS gene was slightly reduced, H3K4me3 was increased at this locus (Fig. 5E ).
Next, we validated our findings at the protein level by quantifying the amount of PE-labeled RANKL. In agreement with our findings at the mRNA level, we observed a significantly lower percentage of RANK + cells and a lower cell surface expression of RANK/cell after exposure of the cells to S100A9 (a mean relative decrease of 75% and 40.7%, respectively; Fig. 6A ). Moreover, we investigated whether S100A9 mediated its inhibitory effect on the expression of RANK via the proinflammatory cytokines IL-1 or TNF-a because both are present in high levels in many inflammatory rheumatic diseases and were induced after S100A9 exposure of monocytes. Addition of IL-1RA to block IL-1 did not restore the S100A9-induced down-regulation of RANK. In contrast, addition of etanercept to block TNF-a resulted in a partial recovery of both the percentage of RANK + cells and the mean cell surface expression/cell (a relative mean 123.3% and 19.2% increase, respectively, compared with S100A9 exposure alone; Fig. 6B ).
DISCUSSION
In this paper, we provide evidence that the alarmin S100A9 hampers the differentiation of circulating CD14+ progenitors into osteoclasts. Moreover, we found that the mechanistic basis could be from a S100A9-mediated reduction of the RANK receptor expression on the surface of M-CSF-stimulated osteoclast progenitors. Finally, we show that the resulting cells secrete high levels of proinflammatory and catabolic factors early after exposure to S100A9, but decreased levels of the osteoclast-stimulating factor TNF-a upon long-term exposure.
Proinflammatory mediators, such as IL-1b, IL-8, TNF-a, and LPS, are generally thought to stimulate osteoclast differentiation and activity (15) (16) (17) (36) (37) (38) . Moreover, in a previous study, our lab described that addition of S100A8 later during in vitro osteoclastogenesis stimulated the further fusion and activation of mature osteoclasts (30) . Alarmins, including S100A8/A9, have been described to be among the first responders during inflammation and to strongly activate cells of the immune system to produce proinflammatory factors (39) . Indeed, exposure of human macrophages to S100A9 increases the expression of various proinflammatory factors, such as IL-1b, IL-8, and TNF-a, and here we show comparable results for human monocytes. As such, S100A9 might be involved in stimulating osteoclastogenesis (27) . In this context, it should be mentioned again that the physiologically relevant form of S100A8 and S100A9 is the heterodimer, which is short-lived in activity and for this reason is not suitable for cell culture studies in which a bolus of recombinant factors is added. Homodimers, which do not inactivate by themselves by oligomer formation, are therefore adequate S100-based damage-associated molecular patterns to investigate fully and constitutively active heterodimers (31) . Interestingly however, in this study, we introduce the concept that S100A9 is not only involved in the promotion of osteoclast differentiation and activation during sterile inflammation. Our data show that exposure of monocytic osteoclast precursors to S100A9 hampered their differentiation into active multinucleated osteoclasts. In agreement with our findings Figure 3 . Long-term exposure to S100A9 leads to a decreased proinflammatory response. CD14+ monocytes, isolated from buffy coats, were differentiated toward osteoclasts with the continuous presence of 25 ng/ml M-CSF and, from d 1, 50 ng/ml RANKL in the presence or absence of 1 mg/ml S100A9 for 4 d from the start of the culture. Protein secretion into the supernatant was quantified by Luminex analysis. Interestingly, this showed that exposure to S100A9 decreased the protein secretion of the osteoclast-stimulating cytokine TNF-a, whereas protein secretion of IL-1b and IL-6 was still increased compared with control samples that were not exposed to S100A9 (n = 11 independent donors), albeit to a lesser extent than after 16 h. Moreover, IL-10 secretion was decreased. Before-after graphs are shown, with samples from the same donor connected with lines. ***P , 0.001 vs. control samples without S100A9 as measured by Wilcoxon matched-pairs signed rank test.
here, a previous study showed that LPS, which like S100A8/A9 is a TLR4 agonist, inhibits differentiation of osteoclasts from murine bone marrow cells and human CD14+ monocytes, emphasizing the possible importance of TLR4 signaling in this process (36, 40) . However, LPS is only a relevant stimulus in septic bone diseases, whereas most osteoclast-associated conditions, including a plethora of arthritis, involve sterile inflammatory conditions in which S100A8/A9 is strongly increased. Other factors that have been described to inhibit precursor-to-osteoclast differentiation are IL-1b and TNF-a (41, 42) . Together, these studies suggest that the timing of exposure to proinflammatory factors like S100A8/A9 in the course of osteoclast differentiation might act as a switch to determine the osteoclast fate.
Both M-CSF and RANKL signaling are required for the survival, proliferation, differentiation, and activation of osteoclasts by binding to the M-CSF and RANK receptor, respectively (1, 10) . Moreover, M-CSF increases the membrane expression of RANK, thus preparing the cell for osteoclast differentiation (10) . The importance of M-CSF signaling is underlined by the finding that mice that lack the M-CSF and as a consequence have a severe deficiency of osteoclasts reveal an osteopetrotic phenotype (7) . In the same line, mice deficient of the Tnfrs11a gene encoding RANK are characterized by a block in osteoclast differentiation Figure 4 . Already, a short-term exposure to S100A9 impedes monocyte-to-osteoclast differentiation. CD14+ monocytes were isolated from buffy coats and differentiated toward osteoclasts in the continuous presence of 25 ng/ml M-CSF and 50 ng/ml RANKL from d 1. Cells were stimulated with 1 mg/ml S100A9 for the first 16 h of culture. A, B) TRAP staining showed that only a 16-h exposure to S100A9 was sufficient to decrease the number of multinucleated osteoclasts (cells with $3 nuclei) at both d 6 (A) and 8 (B) in comparison with control samples that were not exposed to S100A9 (n = 8 independent donors), although d 8 did not reach significance. C ) Underlining this reduced number of osteoclasts, resorption (n = 10 independent donors) was significantly decreased at d 10, as determined with hydroxyapatite-like-coated plates. Photomicrographs in A and B show representative examples of TRAP stainings, whereas photomicrographs in C show representative examples of Von Kossa stainings of hydroxyapatite-like-coated plates. Before-after graphs are shown in A-C, with samples from the same donor connected with lines. *P , 0.05, ***P , 0.001 vs. control samples without S100A9 as measured by paired t test (TRAP) and Wilcoxon matchedpairs signed rank test (resorption). Figure 5 . S100A9 decreases the expression of TNFRSF11A but not C-FMS. CD14+ monocytes were isolated from buffy coats and cultured with 25 ng/ml M-CSF in the presence or absence of 1 mg/ml S100A9 for 16 h for RNA expression. For ChIP, 50 ng/ml RANKL was added to the cultures for an additional 4 h. Gene expression was determined with RNA sequencing. A) Pathway analysis showed that C-FMS, the gene encoding the M-CSF receptor, was not decreased after exposure to S100A9. In contrast, (continued on next page) resulting in severe osteopetrosis (13) . Moreover, blocking the RANKL-RANK interaction with an antibody efficiently decreases osteoclast-mediated bone resorption (43) . Pathway analysis revealed that S100A9 exposure decreased the expression of the RANK-encoding TNFRSF11A gene and its downstream signaling. However, next to the RANK-RANKL pathway, osteoclast differentiation is regulated by a co-stimulatory pathway in which the g-chain plays an important role. Interestingly, pathway analysis showed an increased expression of this g-chain, which associates with, among others, activating Fc-g receptors and as such is involved in proinflammatory signaling and osteoclast differentiation (44) . A previous study from our lab indeed showed increased expression of activatory Fc-g receptors upon S100A8 exposure of murine macrophages (45) . These data suggest that it is unlikely that the inhibition of osteoclast differentiation is the result of S100A9-induced changes in the co-stimulatory pathway but rather the result of an S100A9-mediated Figure 6 . Reduced membrane RANK expression upon exposure to S100A9. CD14+ monocytes were obtained from healthy buffy coats and treated with 25 ng/ml M-CSF and either stimulated with 1 mg/ml S100A9 or left untreated for 16 h. RANK was determined using PE-labeled RANKL. A) Flow cytometric analysis (n = 11 independent donors) showed that both the percentage of positive cells and the mean fluorescence intensity (MFI) was significantly decreased in S100A9-treated samples compared with control samples without S100A9. B) Addition of 10 mg/ml etanercept to inhibit TNF-a showed a partial restoration of both the percentage of RANK + cells and the MFI, whereas addition of 10 mg/ml IL-1RA to inhibit IL-1 did not restore the membrane RANK expression. TNFRSF11A, encoding RANK and its downstream signaling, seemed to be reduced upon S100A9 exposure. B) In agreement, realtime qPCR (n = 8 independent donors) showed that RANK expression strongly increased after culture with M-CSF, but this increase was strongly impeded by exposure of the cells to S100A9. C ) Moreover, C-FMS expression significantly increased after 16 h of culture with M-CSF, but its expression was not changed by exposure to S100A9. D, E ) Underlining these findings, ChIP showed that the promotor marks H3K4me3 and H3K27ac occupancy were decreased at the TNFRSF11A locus (D), whereas they were unaltered at the C-FMS locus (E ) after 1 d of differentiation toward osteoclasts upon S100A9 treatment (bottom line for each mark) compared with control samples without S100A9 (upper line for each mark). Before-after graphs are shown in B and C, with samples from the same donor connected with lines. *P , 0.05, **P , 0.01, ***P , 0.001 vs. control samples without S100A9 as measured by a repeated-measures 1-way ANOVA, followed by a Tukey multiple comparison.
reduction in the expression of RANK-RANKL signaling, which we next investigated more extensively. This showed that exposure to S100A9 for only the first 16 h of culture already strongly decreased the membrane expression of RANK and thus most probably decreased the intracellular signaling that is crucial for osteoclast differentiation. This decreased RANK expression might be explained by our findings that both H3K4me3 and H3K27ac were decreased at the TNFRSF11A gene. In contrast, although we observed slightly decreased H3K27ac and slightly increased H3K4me3 at the C-FMS locus, qPCR data showed that this did not affect the expression in a bigger set of donors. Together, these data indicate that the S100A9 effects are directly affecting the RANK expression levels rather than indirectly via decreased expression of the M-CSF receptor. Interestingly, we showed that both IL-1b and TNF-a secretion were increased after exposure to S100A9, which has been shown to reduce osteoclast differentiation from precursors (41, 42) . However, after exposure to S100A9, addition of IL-1RA to block IL-1 did not rescue the membrane expression of RANK. In contrast, addition of etanercept partially rescued the S100A9-induced down-regulation of RANK. However, this rescue was relatively small as compared with the reduction in RANK expression upon exposure to S100A9, indicating that other mediators or a direct effect of S100A9 are likely involved. Together, given the importance of RANK signaling for osteoclast differentiation, our findings suggest that this reduction in RANK expression might be the mechanism underlying the hampering of osteoclast differentiation, although we cannot irrefutably prove this.
An additional mechanism as to how the exposure to S100A9 might mediate the decrease in osteoclast differentiation was brought to light by our finding that long-term S100A9 activation for 4 d resulted in a decreased secretion of TNF-a in the majority of the tested donors, although this did not reach significance because, for 2 donors, the TNF-a secretion was increased at this time point. Interestingly however, these 2 donors had the lowest basal TLR4 expression of all donors tested immediately after isolation from buffy coats. Interestingly, exposure to S100A9 for only the first 16 h significantly reduced the TNF-a secretion at d 4 (unpublished results). Although addition of TNF-a to osteoclast precursors inhibits osteoclastogenesis, later during this process TNF-a has been shown to promote the differentiation, survival, and resorbing activity of osteoclasts, and TNFa has been described to play an important role in the co-stimulation of osteoclast differentiation next to the RANK-RANKL pathway, all of which could thus be decreased after exposure of osteoclast precursors to S100A9 (15, (46) (47) (48) .
These dampening effects of S100A9 are in line with previous findings. Differentiation of dendritic cells was found to be decreased under the influence of S100A8/A9 (49) . Moreover, relatively long-term activation of phagocytes with S100A8/A9 has been shown to induce stress tolerance under conditions of sterile inflammation (50) .
Although S100A8/A9 has been previously associated with increased bone resorption and increased differentiation and activation of mature osteoclasts, we here show for the first time that exposure of osteoclast precursors to S100A9 strongly inhibits their osteoclastogenic potential, which we found to be associated with a reduced RANK expression. This shifts the dogma that the alarmin S100A8/A9 solely stimulates inflammation, osteoclast formation, and consequent bone resorption more toward a concept in which the timing of exposure to S100A8/A9 is an important determinant for the precursor-to-osteoclast differentiation. The impeding effect of S100A8/A9 described here might therefore be considered as a negative feedback loop on the proinflammatory and stimulatory effects on mature osteoclasts in order to prevent uncontrolled bone resorption under sterile inflammatory conditions.
